Loading patent…
AssigneesOmeros Corporation, University of Leicester
InventorsHans-Wilhelm Schwaeble, Cordula Margaret Stover, Clark E Tedford, James B Parent, Teizo Fujita
Estimating the term…
In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.
A method of inhibiting MASP-2-dependent complement activation in a subject suffering from or age-related macular degeneration, comprising administering to the subject an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation, wherein the MASP-2 inhibitory agent comprises an anti-MASP-2 antibody or fragment thereof that specifically binds to a portion of SEQ ID NO:6.
A method of treating a subject suffering from or age-related macular degeneration comprising administering a composition comprising an amount of an anti-MASP-2 antibody or fragment thereof that specifically binds to a portion of SEQ ID NO:6 effective to inhibit MASP-2-dependent complement activation.
Dependencies are inferred from the claim text.